UPL reported a strong quarter as Ebitda jumped 68% YoY (on a low base) to Rs 32.3 billion, fueled by a strong demand recovery (volume-driven growth; 11% YoY in Q4), better product mix, rebate normalization, and lower cost of goods sold. Despite the challenging macro environment, UPL reported an industry-leading volume growth of ~13% YoY in FY25.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
UPL Ltd. has witnessed resilient growth in H2 FY25 despite macro headwinds. Building on this momentum, the company is likely to experience further growth in FY26 (largely in H2; H1 to be subdued due to geopolitical risks).
This growth will be propelled by healthy volume growth across key regions (North America, LATAM, and ROW), while pricing will remain soft. Further, new product contribution would see a healthy ramp-up, while Advanta Seeds will continue witnessing growth in both existing and new products. We expect revenue/Ebitda/adjusted PAT CAGR at 7%/14%/52% over FY25-27.
Reiterate Neutral with a target price of Rs 660 (based on 11x FY27 EPS).
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

JB Chemicals' Acquisition Strategically Positive For Torrent Pharma, Says Motilal Oswal — Maintains 'Neutral'


Bajaj Auto Q4 Review: Motilal Oswal Maintains 'Neutral', Says KTM Turnaround To Be Among The Key Monitorables

.jpg?rect=0%2C0%2C3500%2C1969&w=75)
KEC International Q4 Review: Motilal Oswal Maintains 'Neutral' On Inline Revenue, Ebitda; Hikes Target Price


Torrent Pharma Q4 Review: Motilal Oswal Maintains 'Neutral', Says Current Valuation Factors In Earnings Upside
